Certolizumab

Phase 3Monoclonal antibody

Johnson & Johnson

Certolizumab is one of 207 small molecule programs targeting Osteomyelitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

206

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteomyelitisActive, not recruiting

Psoriatic ArthritisActive, not recruiting

Rheumatic DiseaseRecruiting

Lung CancerRecruiting

Atopic DermatitisNot yet recruiting

RecurrentRecruiting

OsteomyelitisPreclinical

Active, not recruiting

Psoriatic ArthritisPreclinical

Active, not recruiting

Rheumatic DiseasePhase 2

Recruiting

Lung CancerPhase 2

Recruiting

Atopic DermatitisPhase 3

Not yet recruiting

RecurrentPhase 3

Recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

25 2

Tagrisso

AstraZeneca

Phase 3

19 3

Beyfortus

BeiGene

Phase 3

10 4

Abraxane

Bristol-Myers Squibb

Phase 3

7 5

Tecentriq

Roche

Phase 3

6 6

Imjudo

AstraZeneca

Phase 3

6 7

Alunbrig

Takeda

Phase 3

4 8

DATROWAY

Daiichi Sankyo

Phase 3

2 9

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 10

Lynparza

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Lung Cancer

NCT04991025

Q1 2028

Phase 2Recruiting

Rheumatic Disease

NCT07138898

Q1 2029

Phase 3Recruiting

Rheumatoid Arthritis

NCT03414502

Q2 2029

Phase 3Recruiting

Recurrent

NCT05930613

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)

Completed·UUniversity of Rochester··NCT01098201·5 enrolled

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting·UUniversity of Nebraska·Phase 3·NCT03414502·400 enrolled

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT06028438·103 enrolled

Osteomyelitis1 trial

CHronic Nonbacterial Osteomyelitis International Registry

Recruiting·SSeattle Children's Hospital··NCT04725422·2,000 enrolled

Psoriatic Arthritis1 trial

Ultrasound Enthesitis Response in Psoriatic Arthritis

Completed·BBelfast Health and Social Care Trust··NCT03955861·80 enrolled

Inflammation1 trial

Lipids, Inflammation, and CV Risk in RA

Completed·—··NCT02714881·74 enrolled

Atopic Dermatitis1 trial

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not yet recruiting·UUniversity of California, San Francisco·Phase 4·NCT07352566·10 enrolled

6 more indications

Lung Cancer1 trial

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04991025·60 enrolled

Recurrent1 trial

Certolizumab in Recurrent Implantation Failure (RIF)

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05930613·161 enrolled

Crohn's Disease1 trial

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

Terminated·—··NCT01582568·1 enrolled

Ankylosing Spondylitis1 trial

Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Unknown status·JJagiellonian University·Phase 4·NCT02132234·100 enrolled

Lung Adenocarcinoma1 trial

Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02120807·30 enrolled

Rheumatic Disease1 trial

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Recruiting·NNYU Langone Health·Phase 2·NCT07138898·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Certolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Certolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Certolizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Certolizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q1 2029

Q2 2029

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Osteomyelitis1 trial

Psoriatic Arthritis1 trial

Inflammation1 trial

Atopic Dermatitis1 trial

Lung Cancer1 trial

Recurrent1 trial

Crohn's Disease1 trial

Ankylosing Spondylitis1 trial

Lung Adenocarcinoma1 trial

Rheumatic Disease1 trial

References

Drug Info

Quick Facts

Related News